The trade name is Nuvaxovidthe US company produces it Novavax and a circular from the Ministry of Health signed by the Director of Prevention Gianni Rezza specified how it can be used in the vaccination campaign. There are still millions of Italians who have not even received the first dose and the authorities hope that this vaccine, designed on the basis of more traditional technologies than the innovative products based on messenger RNA, can convince a further share of doubtful, frightened or full-blown no vax to protect themselves from serious illness. I’m 1.3 million people over the age of 50 without a vaccine, despite the fact that they are required to have an injection. But there is a slice of skeptics even in the lower demographics: almost 13% of 40-49 year-olds or 12 of 30-39 year-olds have not yet received the vaccine.
The first million doses are on their way within the week. Nuvaxovid can be used for now only for primary school, therefore for the two initial doses and not for the booster. It is about two intramuscular injections of 0.5 mL each 21 days apart. It has not been approved for use in children and young people, so the Novavax product can be inoculated only from 18 years onwards.
Novavax debuted in November in Indonesia and it was then approved in December by the EMA for the conditional introduction on the market, while in the United States the manufacturer has experienced problems at the plants and postponed the request for emergency approval. The Novavax vaccine, technically known as NVX-CoV2373, is based on the technology of recombinant proteins: molecules capable of assembling to form virus-like particles on the basis of which the organism produces its immune response, triggering the formation of antibodies. In other words, starting from a specific RNA sequence of the virus, artificial spike proteins are made in the laboratory that are able to assemble into nanoparticles, which in turn are able to mimic the structure of Sars-CoV-2. Obviously without being able to replicate or cause the disease.
Each Nuvaxovid multidose vial contains 10 doses of 0.5 mL, does not require dilution and is therefore immediately ready for use. The closed container, stored in the refrigerator at a temperature between 2 and 8 degrees centigrade, is valid for 9 months. At room temperature up to 25 degrees it should be used within 12 hours. Finally, after the first opening, it can be stored at a temperature between and 25 degrees and can be used within 6 hours.
Other stories of Vanity Fair that may interest you
New Novavax vaccine: how the anti-Covid product authorized in Indonesia works
Walter Ricciardi: “Probable fourth anti-Covid dose for everyone in the autumn”
Source: Vanity Fair
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
